From the Institute of Surgical Gastroenterology & Liver Transplantation, Centre for GI Bleed, Division of HPB Diseases, Stanley Medical College Hospital, Chennai, India.
Ann Surg. 2015 Jul;262(1):31-7. doi: 10.1097/SLA.0000000000001077.
Postoperative infectious complications in patients undergoing pancreatic surgery are a significant cause for morbidity and mortality. Although synbiotics have beneficial effects on human health, their clinical value in surgical patients remains unclear given a paucity of applicable clinical studies.
To determine the impact of perioperative synbiotic therapy on postoperative infectious complications, morbidity and mortality in patients undergoing pancreatic surgery for chronic pancreatitis.
A trial was conducted in patients with chronic calcific pancreatitis undergoing Frey's procedure. Group A received a specific synbiotic composition, 5 days prior and 10 days after the surgery. Group B received a placebo. Primary study endpoint was the occurrence of postoperative infection during the first 30 days. Secondary outcome measures were mortality, length of hospital stay, days in intensive care unit, and duration of antibiotic therapy. Using previously accrued data, with α of 0.05 and power 80%, the sample size was calculated as 35 patients for each group with a dropout rate of 10%.
Of the 79 patients enrolled, 75 completed the trial [group A (n = 39) and group B (n = 36)]. The incidence of postoperative infectious complications (12.8% vs 39%; P < 0.05), duration of antibiotics therapy (P < 0.05), and length of hospital stay (P < 0.05) were significantly lower in the synbiotic group.
Synbiotics significantly reduce septic complications, hospital stay, and antibiotic requirement in patients undergoing pancreatic surgery for chronic pancreatitis. Furthermore, basic and clinical research would clarify the underlying mechanisms of their therapeutic effect and define the appropriate conditions for use.
胰腺手术后患者的术后感染并发症是发病率和死亡率的重要原因。尽管共生元对人类健康有益,但由于缺乏适用的临床研究,其在外科患者中的临床价值尚不清楚。
确定围手术期共生元治疗对慢性胰腺炎行胰腺手术患者术后感染并发症、发病率和死亡率的影响。
对行 Frey 手术的慢性钙化性胰腺炎患者进行了一项试验。A 组在手术前 5 天和手术后 10 天接受特定的共生元组成,B 组接受安慰剂。主要研究终点是术后 30 天内发生的术后感染。次要结局指标是死亡率、住院时间、重症监护病房天数和抗生素治疗时间。使用以前累积的数据,α 为 0.05,功率为 80%,计算出每组 35 名患者(脱落率为 10%)的样本量。
79 名入组患者中,75 名完成了试验[A 组(n=39)和 B 组(n=36)]。共生元组术后感染并发症的发生率(12.8% vs 39%;P<0.05)、抗生素治疗时间(P<0.05)和住院时间(P<0.05)明显降低。
共生元可显著减少慢性胰腺炎行胰腺手术患者的脓毒症并发症、住院时间和抗生素需求。此外,基础和临床研究将阐明其治疗效果的潜在机制,并确定其使用的适当条件。